NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Pre-Mkt 12-19 06:45:54 EST

19.28

+0.14

+0.73%

High20.33	Low19.13	Vol223.68K
Open19.54	D1 Closing19.14	Amplitude6.26%
Mkt Cap298.64M	Tradable Cap116.02M	Total Shares15.49M
T/O4.36M	T/O Rate3.72%	Tradable Shares6.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":19.28,"timestamp":1766091600000,"preClose":19.14,"halted":0,"volume":223682,"delay":0,"floatShares":6017500,"shares":15489800,"eps":-4.120047,"marketStatus":"Pre-Mkt","change":0.14,"latestTime":"12-19 06:45:54 EST","open":19.54,"high":20.328,"low":19.13,"amount":4359474.272974,"amplitude":0.062591,"askPrice":23.01,"askSize":100,"bidPrice":15.57,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.120047,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":19.28,"postHourTrading":{"tag":"盘后","latestPrice":19.28,"preClose":19.28,"latestTime":"17:40 EST","volume":4920,"amount":94857.85,"timestamp":1766097655272},"volumeRatio":1.1650261922135214,"impliedVol":0.1254,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/NGNE/tweets","defaultTab":"tweets","newsList":[{"id":"2589832071","title":"Neurogene Grants Stock Options to New Employees Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2589832071","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589832071?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:01","pubTimestamp":1764882071,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has approved the grant of non-qualified stock options to purchase a total of 4,860 shares of the company's common stock for two new employees. These options have an exercise price equal to the closing price of Neurogene's shares on the grant date and will vest over four years: 25 percent will vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLzWXSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2589061832","title":"Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589061832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589061832?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:01","pubTimestamp":1764882060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA7JF56M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2584922459","title":"Neurogene Q3 EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922459","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922459?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:42","pubTimestamp":1763574122,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Neurogene Q3 net income USD -20.953 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202522:10:45.873 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDc9whDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583100985","title":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583100985","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583100985?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:26","pubTimestamp":1763072779,"startTime":"0","endTime":"0","summary":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853048/neurogene-q3-eps-0-99-beats-1-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583783510","title":"Gene therapy developer Neurogene's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583783510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583783510?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:20","pubTimestamp":1763072409,"startTime":"0","endTime":"0","summary":"Gene therapy developer Neurogene's Q3 net loss widensOverviewCompany maintains strong cash position, funding operations through Q1 2028Net loss for Q3 2025 was $21.0 mln, slightly higher than Q3 2024O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP1D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583510676","title":"BRIEF-Neurogene Q3 EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510676","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510676?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071845,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q3 EPS USD -0.99\n\n\nNov 13 (Reuters) - Neurogene Q3 net income USD -20.953 million.\n\nQ3 operating expenses USD 23.798 million\nQ3 operating income USD -23.798 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX0792C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583851098","title":"Neurogene reports positive interim data from NGN-401 Phase 1/2 trial for Rett syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2583851098","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583851098?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071825,"startTime":"0","endTime":"0","summary":"Neurogene Inc. reported a net loss of $21.0 million for the third quarter ended September 30, 2025, compared to a net loss of $20.2 million for the same period in 2024. Cash, cash equivalents, and short-term investments totaled $265.4 million as of September 30, 2025. The company expects its current cash position to fund planned operations through the first quarter of 2028. During the period, Neurogene announced positive interim data from the NGN-401 Phase 1/2 gene therapy trial for Rett syndrome and began dosing participants in the Embolden registrational trial, with full enrollment anticipated within three to six months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL38m9Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583606510","title":"Neurogene Q3 Operating Income USD -23.798 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583606510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583606510?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX0792C3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583106035","title":"Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583106035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583106035?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA3CY09T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583956795","title":"Stifel Nicolaus Remains a Buy on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583956795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583956795?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:56","pubTimestamp":1763042186,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurogene, with a price target of $46.00. Matteis covers t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","NGNE","BK4139","SF"],"gpt_icon":0},{"id":"2583609145","title":"Neurogene Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583609145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583609145?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:54","pubTimestamp":1763038440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 07:54 ET (12:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583300453","title":"Neurogene Reports Positive Interim Results for NGN-401 Gene Therapy in Pediatric Rett Syndrome Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583300453","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583300453?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981319,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. The data, drawn from the pediatric cohort , indicate that all eight participants experienced functional gains and acquired a total of 35 developmental milestones or skills across varying levels of disease severity. The reported improvements have shown durability, with continued skill acquisition observed over time and sustained gains up to 24 months post-treatment. NGN-401 at the registrational dose has been generally well-tolerated, with no evidence of HLH. Neurogene management will discuss these results and the Embolden registrational trial at the Stifel 2025 Healthcare Conference. The webcast presentation is scheduled for today at 4:40 p.m. ET, with a replay to be available on the company's website. Additional clinical data are expected to be reported in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3MprZ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583585537","title":"Neurogene Inc - Ngn-401 Well-Tolerated With No Evidence of Hlh","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585537?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9YSFBX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583300131","title":"Neurogene Reports Positive Interim Data in Pediatric Cohort From Ngn-401 Gene Therapy Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2583300131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583300131?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9YSFBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2581016556","title":"Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581016556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581016556?lang=en_us&edition=fundamental","pubTime":"2025-11-07 01:40","pubTimestamp":1762450812,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurogene (NGNE – Research Report) and Ironwood Pharma (IRWD – Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-ironwood-pharma-irwd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurogene-ngne-and-ironwood-pharma-irwd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4581","NGNE","BK4585","HCSG","XLV","BK4137","BK4139","IRWD","XBI","BK4588","LABU","LU0128526141.USD"],"gpt_icon":0},{"id":"2581306057","title":"Neurogene Doses First Participant in Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2581306057","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581306057?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:31","pubTimestamp":1762432314,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has announced the dosing of the first participant in the Embolden registrational clinical trial of NGN-401, a gene therapy candidate for the treatment of Rett syndrome. Embolden is a single-arm, open-label, baseline-controlled trial evaluating a 1E15 vector genome dose of NGN-401 in 20 females aged three years and older. Enrollment for the trial is underway in the U.S., with completion expected within three to six months. Interim data from the Phase 1/2 trial of NGN-401 will be presented by company management at the Stifel 2025 Healthcare Conference on November 12, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on Nove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL52CM4W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4139","BK4127","NGNE"],"gpt_icon":0},{"id":"2581606700","title":"Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of Ngn-401 Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2581606700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581606700?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA2XLMKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2581709976","title":"Neurogene Grants Stock Options to New Employee Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709976?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:02","pubTimestamp":1762376536,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has granted non-qualified stock options to purchase 1,185 shares of its common stock to a new employee. The options have an exercise price equal to the closing price of Neurogene's common stock on the grant date of November 4, 2025. The options will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal portions every three months over the following 36 months, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL53f64F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2581709613","title":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709613?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376463,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA7BCRGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2581763453","title":"FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2581763453","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581763453?lang=en_us&edition=fundamental","pubTime":"2025-11-05 03:25","pubTimestamp":1762284300,"startTime":"0","endTime":"0","summary":"William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/04/Concept-Of-Huntingtons-Disease-Write-On-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/04/Concept-Of-Huntingtons-Disease-Write-On-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/25/11/48633448/fdas-rigid-approach-adds-uncertainty-to-uniqures-accelerated-pathway-for-huntingtons-gene-therapy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/25/11/48633448/fdas-rigid-approach-adds-uncertainty-to-uniqures-accelerated-pathway-for-huntingtons-gene-therapy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["PSQ","BK4139","NVIW.SI","QURE",".IXIC","TSYW.SI","QID","CABA","NQmain","NGNE","USAW.SI","RCKT","LU0109394709.USD","QLD","SQQQ","LU0320765992.SGD","USJW.SI","KYTX","LU0889565916.HKD","TQQQ","MNQmain"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.0931},{"period":"1month","weight":-0.0974},{"period":"3month","weight":0.1209},{"period":"6month","weight":0.0856},{"period":"1year","weight":-0.1152},{"period":"ytd","weight":-0.1566}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.051789},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.050266},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037124},{"month":4,"riseRate":0.25,"avgChangeRate":-0.076909},{"month":5,"riseRate":0.5,"avgChangeRate":0.000899},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.072235},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055031},{"month":8,"riseRate":0.833333,"avgChangeRate":0.776521},{"month":9,"riseRate":0.25,"avgChangeRate":-0.065331},{"month":10,"riseRate":0.416667,"avgChangeRate":0.020322},{"month":11,"riseRate":0.416667,"avgChangeRate":0.000025},{"month":12,"riseRate":0.583333,"avgChangeRate":0.142269}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction